Ketamine's antidepressant action relies on TrkB/mGluR5 cross-talk, boosting synaptic potentiation

Effective treatments for major depressive disorder often target complex neuromodulatory systems, yet a full understanding of their intricate interactions remains elusive. While ketamine offers rapid antidepressant effects, its precise synaptic mechanisms, particularly how different receptor classes cooperate, are not fully mapped. This gap limits the development of more targeted therapies with fewer side effects. This research specifically investigates the interplay between the receptor tyrosine kinase TrkB (a primary receptor for BDNF) and the G protein-coupled receptor mGluR5, aiming to uncover how their functional cross-talk contributes to ketamine's therapeutic action.

Researchers investigated the intricate interplay between the tropomyosin-related kinase B (TrkB) receptor and the metabotropic glutamate receptor 5 (mGluR5), focusing on their role in mediating ketamine's antidepressant effects. The study explored how brain-derived neurotrophic factor (BDNF) signaling influences TrkB and mGluR5 activity, and how these interactions are modulated by ketamine. They also examined the impact of an mGluR5 positive allosteric modulator (PAM) on these cross-talk mechanisms. The investigation centered on synaptic plasticity, specifically assessing mechanisms of synaptic potentiation and depression, alongside changes in surface and postsynaptic TrkB levels.

The study revealed that ketamine's antidepressant action is critically dependent on both TrkB and mGluR5 receptors, operating through two distinct modes of cross-talk. First, mGluR5 was found to amplify BDNF-driven signaling of TrkB, thereby enabling synaptic potentiation via a mechanism termed "signaling cross-talk." This suggests mGluR5 acts as a sensitizer for TrkB's pro-plasticity effects. Second, BDNF activation of TrkB was shown to drive mGluR5 endocytosis, leading to impaired synaptic depression through a process called "trafficking cross-talk." This indicates a reciprocal regulation where TrkB activity can desensitize mGluR5's depressive effects. Both of these beneficial cross-talk modes were significantly enhanced by ketamine, which also increased the surface and postsynaptic levels of TrkB.